Study of MEDI4736 in Subjects with Melanoma

• Research type

  Research Study

• Full title

  A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone

• IRAS ID

  141889

• Contact name

  Paul Nathan

• Contact email

  nathan.pd@gmail.com

• Sponsor organisation

  MedImmune LLC

• Eudract number

  2013-003544-23

• ISRCTN Number

  not provided

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/1724

• Date of REC Opinion

  11 Dec 2013

• REC opinion

  Favourable Opinion